Chiron curtails vaccine distribution for upcoming flu season

After announcing several days ago that it had run into sterility problems at its German facility responsible for producing the Begrivac flu vaccine, Chiron now says that it won't be able to provide any of that vaccine outside of the US for the upcoming flu season. Chiron says it will look to other products to make up for the shortfall. The move comes soon after Chiron sharply cut its forecasted production of Fluvirono.

- read this report from TheStreet.com for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.